8-K: Cytek Biosciences Reports Modest Revenue Growth and Improved Profitability in 2024, Issues 2025 Outlook

Cytek Biosciences reports a 3.9% increase in full-year 2024 revenue and a significant improvement in adjusted EBITDA, while providing a 2025 revenue outlook of $204 million to $212 million.

Summary

• Cytek Biosciences reported its financial results for the fourth quarter and full year ended December 31, 2024.
• Total revenue for the full year 2024 was $200.5 million, a 3.9% increase over 2023, or $201.3 million on a non-GAAP constant currency basis.
• The company expanded its installed base to 3,034 instruments, placing 667 instruments during the year.
• Net loss for the year was $6.0 million, an improvement from the $12.1 million loss in 2023.
• Adjusted EBITDA for the year was $22.4 million, a 77% increase over 2023, and $14.4 million excluding investment income, a 128% increase.
• Cytek opened a new manufacturing facility in Singapore to lower costs and increase supply flexibility.
• The company repurchased 3,971,624 shares of common stock for approximately $21.6 million from June through year-end 2024.
• A new stock repurchase program for up to an additional aggregate of $50 million was announced for 2025.
• For the fourth quarter of 2024, total revenue was $57.5 million, a 1.3% decrease from the same period in 2023, but $58.6 million on a non-GAAP constant currency basis, a 1.4% increase.
• Gross profit for the fourth quarter was $33.7 million, a 1.8% increase, with a gross margin of 59%.
• Cytek expects total revenue for 2025 to be in the range of $204 million to $212 million, representing growth of 2% to 6%.

Sentiment

Score: 7

Explanation: The document presents a mixed picture with modest revenue growth but significant improvement in profitability and a positive outlook for 2025. The stock repurchase program and new manufacturing facility are also positive signals.

Positives

• Total revenue increased by 3.9% to $200.5 million for the full year 2024.
• Adjusted EBITDA saw a substantial increase of 77% to $22.4 million for the full year 2024.
• The installed base of Cytek instruments grew to 3,034.
• A new manufacturing facility in Singapore was opened, which is expected to provide cost advantages and improve supply chain flexibility.
• The company repurchased shares and authorized a new repurchase program, indicating confidence in its financial position.
• Net loss decreased from $12.1 million to $6.0 million year over year.

Negatives

• Fourth quarter revenue decreased by 1.3% compared to the same period in the previous year, although non-GAAP constant currency revenue increased by 1.4%.
• Gross margin decreased from 57% to 55% for the full year.
• The company reported a net loss of $6.0 million for the year, although this was an improvement from the previous year's loss.

Risks

• The company's ability to accurately forecast customer demand and adoption of its products could impact future performance.
• Dependence on sole and single-source suppliers poses a risk to the supply chain.
• Competition in the cell analysis market could affect Cytek's market share and profitability.
• The company's ability to manage growth and complexity, maintain customer and supplier relationships, and retain key employees is crucial for future success.
• Recent and future export controls and licensing requirements, tariffs, and NIH funding policies could impact the business.
• Foreign currency exchange impacts could affect financial results.

Future Outlook

Cytek Biosciences expects total revenue for the year ended December 31, 2025, to be in the range of $204 million to $212 million, representing growth of 2% to 6% over the year ended December 31, 2024, assuming no change in currency exchange rates.

Management Comments

• Dr. Wenbin Jiang, CEO of Cytek Biosciences, stated that he is pleased with the company's continued market penetration, increased instrument deployments, and substantial increase in adjusted EBITDA and positive cash flow generation.
• Dr. Jiang also expressed confidence in the company's long-term objective of delivering sustainable growth and profitability.

Industry Context

Cytek operates in the cell analysis solutions market, which is characterized by technological advancements and increasing demand for high-resolution, high-content, and high-sensitivity cell analysis tools. The company's focus on its patented Full Spectrum Profiling (FSP) technology positions it to compete effectively in this market.

Comparison to Industry Standards

• It is difficult to provide a direct comparison to industry standards without more specific information on Cytek's competitors and their performance metrics.
• However, companies like Danaher, Thermo Fisher Scientific, and Becton Dickinson are major players in the broader life sciences and diagnostics industry, and their growth rates and profitability could serve as benchmarks.
• Cytek's 3.9% revenue growth is modest compared to some high-growth companies in the biotech sector, but its significant improvement in adjusted EBITDA suggests improved operational efficiency.
• The company's installed base growth and expansion into new manufacturing facilities are positive indicators of its competitive positioning.

Stakeholder Impact

• Shareholders may be encouraged by the improved profitability and stock repurchase program.
• Employees may benefit from the company's growth and expansion.
• Customers can expect continued innovation and product development.
• Suppliers may see increased business opportunities as Cytek expands its manufacturing capacity.

Next Steps

• Cytek will host a conference call to discuss its fourth quarter and year-end 2024 financial results.
• The company will continue to execute its growth strategy and focus on delivering sustainable growth and profitability.
• Cytek will continue to monitor and manage the impacts of export controls, licensing requirements, tariffs, and NIH funding policies on its business.

Key Dates